Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 7/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22571356 | 0.84 | MPO (0.52) | MPOAKR1C3AKR1C2RXFP1KDM1A | |
| SCHEMBL21053197 | 0.80 | MPO (0.55) | MPOAKR1C3AKR1C2RXFP1KDM1A | |
| SCHEMBL11435538 | 0.72 | EGFR (0.51) | AKR1C3AKR1C2RXFP1MEN1TSHR | |
| SCHEMBL22556334 | 0.71 | RXFP1 (0.53) | RXFP1TAS2R14MEN1KMT2A | |
| SCHEMBL23701602 | 0.71 | RXFP1 (0.53) | RXFP1 | |
| SCHEMBL22556320 | 0.71 | RXFP1 (0.53) | RXFP1 | |
| SCHEMBL6440422 | 0.70 | GRIK1 (0.62) | MPOAKR1C3AKR1C2KDM1AKCNK2 | |
| SCHEMBL6351486 | 0.70 | KCNK2 (0.73) | MPOAKR1C3AKR1C2RXFP1KDM1A | |
| SCHEMBL30463796 | 0.69 | KMT2A (0.51) | RXFP1KMT2A | |
| SCHEMBL23701612 | 0.69 | RXFP1 (0.50) | RXFP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11524943-B1 | Benzocarbonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3720430-A1 | BENZOCARBONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113236-A1 | BENZOCARBONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524943-B1 | Benzocarbonyl compounds | YAP1, TEAD2, TEAD3 | MPO 3634/4885AKR1C3 4086/4885AKR1C2 3536/4885 |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | MPO 3523/4885AKR1C3 4073/4885AKR1C2 3589/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | MPO 3523/4885AKR1C3 4073/4885AKR1C2 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.